Finance

EQT backs out of takeover bid for UK's Oxford Biomedica

Published by Global Banking & Finance Review

Posted on February 25, 2026

1 min read

· Last updated: April 2, 2026

Add as preferred source on Google
EQT backs out of takeover bid for UK's Oxford Biomedica
Global Banking & Finance Awards 2026 — Call for Entries

Feb 25 (Reuters) - Private equity group EQT said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica, sending the British cell and gene therapy manufacturer's shares

EQT Walks Away From Takeover Bid for UK’s Oxford Biomedica plc

Decision Announced on Feb 25, 2026

EQT Ends Oxford Biomedica Takeover Talks

Feb 25 (Reuters) - Private equity group EQT said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica, sending the British cell and gene therapy manufacturer's shares down nearly 10%.

Byline and Attribution

(Reporting by Ankita Bora in Bengaluru; Editing by Shreya Biswas)

Key Takeaways

  • EQT decided not to proceed with a takeover of Oxford Biomedica.
  • The Rule 2.8 statement restricts EQT from making another offer for a period unless exceptions apply.
  • Oxford Biomedica shares fell nearly 10% on the news.
  • The PUSU deadline had been extended to Feb 25, 2026, before EQT withdrew.
  • No financial terms or reasons for withdrawal were disclosed.

References

Frequently Asked Questions

What is the main topic?
EQT decided not to proceed with a takeover of Oxford Biomedica on Feb 25, 2026, which led to a near-10% drop in the biotech firm’s shares.
Why did EQT withdraw its offer?
EQT issued a Rule 2.8 statement saying it does not intend to make an offer. The announcement did not disclose reasons or terms.
What are the implications under UK takeover rules?
After a Rule 2.8 statement, EQT is generally restricted for six months from making another offer unless exceptions apply, such as a third-party bid or board consent.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category